Algeta enters research collaboration to evaluate thorium conjugated with a novel tumor-targeting antibody from Genzyme

05-Apr-2011 - Norway

Bubble-free column packing for pilot scale

Individually packed chromatography columns for maximum efficiency

High-throughput and high-sensitivity applications with Biacore 8 series 16 flow-cell SPR systems

Algeta ASA announced that it has entered a research collaboration with Genzyme to evaluate the potential of its thorium platform.

Under the terms of the collaboration, Genzyme will provide access to a novel and proprietary tumor-targeting antibody, and Algeta will provide access to its Thorium platform to attach the alpha emitting payload thorium-227. Both companies will contribute resources towards the collaboration, which is expected to last for up to a year initially.

Thomas Ramdahl, Executive Vice President and Chief Technology Officer, said: "We are delighted to work with Genzyme on this important new approach to cancer treatment, which combines our cancer-killing payload thorium-227 with the novel antibody's own target specificity and tumor cell degradation properties. Algeta has previously demonstrated the promise of our alpha-emitter thorium-227 as a payload and we now look forward to applying our Thorium platform to this novel antibody."

https://www.bionity.com/en/news/131773/algeta-enters-research-collaboration-to-evaluate-thorium-conjugated-with-a-novel-tumor-targeting-antibody-from-genzyme.html